Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
In the latest session, Caribou Biosciences Inc (NASDAQ: CRBU) closed at $1.93 up 14.20% from its previous closing price of $1.69. In other words, the price has increased by $14.20 from its previous closing price. On the day, 1.36 million shares were traded. CRBU stock price reached its highest trading level at $1.965 during the session, while it also had its lowest trading level at $1.69.
Ratios:
For a deeper understanding of Caribou Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.66 and its Current Ratio is at 6.66. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for the company, Evercore ISI on June 03, 2024, Downgraded its rating to In-line and sets its target price to $3 from $13 previously.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 14 ’25 when Haurwitz Rachel E. bought 20,000 shares for $1.02 per share. The transaction valued at 20,400 led to the insider holds 3,369,395 shares of the business.
MCCLUNG BARBARA G sold 3,564 shares of CRBU for $4,811 on Feb 21 ’25. The Chief Legal Officer now owns 443,502 shares after completing the transaction at $1.35 per share. On Feb 21 ’25, another insider, Khan Ruhi Ahmad, who serves as the Chief Business Officer of the company, sold 3,564 shares for $1.35 each. As a result, the insider received 4,811 and left with 66,936 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRBU now has a Market Capitalization of 179727856 and an Enterprise Value of 21630852. For the stock, the TTM Price-to-Sale (P/S) ratio is 19.71 while its Price-to-Book (P/B) ratio in mrq is 1.08. Its current Enterprise Value per Revenue stands at 2.372 whereas that against EBITDA is -0.148.
Stock Price History:
The Beta on a monthly basis for CRBU is 2.52, which has changed by 0.005208373 over the last 52 weeks, in comparison to a change of 0.1675967 over the same period for the S&P500. Over the past 52 weeks, CRBU has reached a high of $3.00, while it has fallen to a 52-week low of $0.66. The 50-Day Moving Average of the stock is 0.48%, while the 200-Day Moving Average is calculated to be 35.57%.
Shares Statistics:
For the past three months, CRBU has traded an average of 1.44M shares per day and 892450 over the past ten days. A total of 93.12M shares are outstanding, with a floating share count of 81.90M. Insiders hold about 12.06% of the company’s shares, while institutions hold 40.84% stake in the company. Shares short for CRBU as of 1756425600 were 4030604 with a Short Ratio of 2.79, compared to 1753920000 on 3895329. Therefore, it implies a Short% of Shares Outstanding of 4030604 and a Short% of Float of 4.5300003.
Earnings Estimates
A comprehensive evaluation of Caribou Biosciences Inc (CRBU) is underway, with the input of 1.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.29 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.64 and -$1.64 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$1.71, with 1.0 analysts recommending between -$1.71 and -$1.71.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for CRBU’s current fiscal year. The highest revenue estimate was $14M, while the lowest revenue estimate was $5M, resulting in an average revenue estimate of $9.84M. In the same quarter a year ago, actual revenue was $9.99M
